Vanda Pharmaceuticals Inc VNDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
-
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
-
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
-
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
-
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
-
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
-
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
-
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Trading Information
- Previous Close Price
- $5.88
- Day Range
- $5.61–5.93
- 52-Week Range
- $4.14–9.94
- Bid/Ask
- $5.68 / $5.73
- Shares Outstanding
- 60.14M
- Market Cap
- $344.58M
- Volume/Avg
- 944,588 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 533
- Website
- https://www.vandapharma.com
Valuation
|
Metric
|
VNDA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.26 |
Price/Sales | 1.59 |
Price/Cash Flow | — |
Price/Earnings
VNDA
Financial Strength
|
Metric
|
VNDA
|
|---|---|
Quick Ratio | 1.91 |
Current Ratio | 2.16 |
Interest Coverage | — |
Quick Ratio
VNDA
Profitability
|
Metric
|
VNDA
|
|---|---|
Return on Assets (Normalized) | −41.79% |
Return on Equity (Normalized) | −56.09% |
Return on Invested Capital (Normalized) | −54.51% |
Return on Assets
VNDA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Dbkmwnpn | Xxyftbq | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Frqzknhf | Xjdzc | $64B | |||
| argenx SE ADR
ARGX
| Vhsbrgl | Tmyk | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pgcywky | Fwwvlx | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Zgbbrzckwq | Cwtpxp | $24B | |||
| BioNTech SE ADR
BNTX
| Dhyqpzsbq | Lfwvw | $23B | |||
| Incyte Corp
INCY
| Pctxtgns | Qdwc | $22B | |||
| Moderna Inc
MRNA
| Nxtrfxlb | Fkd | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Tnknmplh | Pysmq | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Djshqxh | Nnwb | $13B |
United States